I'm listening to Warren Buffett and loading up on cheap ASX shares in March

I love the look of these stocks at these prices.

| More on:
A young woman dressed in street clothes leaps happily in the air with the focus on her bright red boots that are front and centre for the camera.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Warren Buffett has always advocated that investors should buy businesses at a price that's less than they're worth. I think some Aussie companies look like cheap ASX shares following their recent reports.

I only like to look at businesses I think can grow over the long term, meaning they'll be more valuable in three years or five years than today. With that in mind, when the share prices fall, it seems like a good opportunity for me to buy.

Johns Lyng Group Ltd (ASX: JLG)

The Johns Lyng share price is down 10% since 26 February 2024.

The business specialises in restoring a building and its contents after damage by an insured event, including flooding, storms and fire. It's also growing its presence in the catastrophe work industry.

I saw several things in the HY24 result that cemented my belief it has an exciting future.

Its core business as usual (BAU) revenue rose 13.7% to $426.1 million, though total revenue declined 4% because catastrophe revenue was lower. Core BAU earnings before interest, tax, depreciation and amortisation (EBITDA) rose 28.1% to $55 million and total EBITDA grew 7.5% to $63.9 million – that's good evidence of operating leverage.

The ASX share also reported that its BAU normalised net profit after tax (NPAT) rose 15.8% to $25 million. If this number can keep growing by double-digits (in percentage terms), then the compounding can enable Johns Lyng to generate much bigger profits in the coming years.

I was also pleased to see that the company is continuing to make acquisitions in the strata management space. Not only does this mean it can create consistent, resilient earnings, but it can also unlock synergies with the core business by utilising those services. I think Warren Buffett would be a fan of this business.

In my opinion, this short-term pullback is a good buy-point for this cheap(er) ASX share. I'm planning to buy more Johns Lyng shares next week.  

Accent Group Ltd (ASX: AX1)

The Accent share price is down 13% from 14 February 2024.

The business continues to add stores across the brands that it owns as well as shoe brands it acts as a distributor for. In the first half of FY24, it saw a total of 72 new stores added. Accent said 22 new Platypus stores have been opened in Australia and New Zealand, along with 17 new Skechers stores.

The ASX share also saw its contactable customers increase by 0.2 million to 10 million.

It saw its gross profit margin improve from 55.2% to 56.6%, which was enough for the business to report a $2 million increase in its gross profit.

While other profit measures decreased, partly due to the inflation of costs, I think the business has a promising future once retail conditions improve.

Its dividend payment of 8.5 cents per share is still an attractive level of passive income.

The trading update was promising. It said total owned sales in the year to date to the end of January 2024 were up 1.6%, while like-for-like sales for the second half were down just 0.7%. The gross profit margin continues to be above last year, while costs continue to be higher, though at a lower rate of increase compared to the first half.

I'm planning to buy some more Accent shares next week. I think this is a very cheap ASX share.  

Motley Fool contributor Tristan Harrison has positions in Accent Group and Johns Lyng Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Johns Lyng Group. The Motley Fool Australia has recommended Accent Group and Johns Lyng Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

a hand reaches out with australian banknotes of various denominations fanned out.
Dividend Investing

These 2 ASX dividend shares are great buys right now

These defensive names look like strong picks today.

Read more »

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX 200 shares that could be top buys for growth

These two businesses have an exciting future.

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

This ASX 200 share is being labelled one of the market's most undervalued by brokers

NextDC shares have pulled back sharply, but brokers believe the long-term growth story remains firmly on track.

Read more »

Hand holding out coal in front of a coal mine.
Energy Shares

Up 25% in 2025: Is Whitehaven Coal still a buy?

After a strong 25% run this year, investors are asking whether Whitehaven Coal still has more upside left.

Read more »

Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
Opinions

5 ASX shares I'd buy with $10,000 this week

These are the ASX stocks I have my eye on this week.

Read more »

bull market model with a bull looking at a rising chart
Opinions

By December 2026, $1,000 invested in EOS shares could be worth…

With its share price taking off and contracts piling up, EOS is shaping up as one of the most compelling…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »